Combination Therapy With Two Biologicals

Tampere University Hospital

Status: Completed

Conditions: IBD

Treatments: Biological: dual biological therapy

Study type: Observational

Funder types: Other

Identifiers

NCT05135221

CBT

Details and patient eligibility

About

The efficacy and safety of dual biological therapy.

Full description

Data of all patients treated with the combination of two biologicals in four Finnish tertiary centres were collected and analysed. Inclusion criteria were simultaneous use of two biological treatments (infliximab, adalimumab, golimumab, vedolizumab or ustekinumab), age 16 years or over and follow-up for at least induction period after introduction of second biological therapy. The primary outcome was effectiveness, defined as remission assessed by physician after at least four months of DBT. The secondary outcome was safety defined by any adverse events or infection complications during DBT.

Enrollment: 16 patients

Sex: All

Ages: 16+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Simultaneous use of two different biological treatments for IBD.
• Treatment duration with combination therapy for at least for induction period.

Exclusion criteria

-Age under 16 years.